142 related articles for article (PubMed ID: 24518821)
1. A novel allosteric mechanism in the cysteine peptidase cathepsin K discovered by computational methods.
Novinec M; Korenč M; Caflisch A; Ranganathan R; Lenarčič B; Baici A
Nat Commun; 2014; 5():3287. PubMed ID: 24518821
[TBL] [Abstract][Full Text] [Related]
2. Probing the activity modification space of the cysteine peptidase cathepsin K with novel allosteric modifiers.
Novinec M; Lenarčič B; Baici A
PLoS One; 2014; 9(9):e106642. PubMed ID: 25184245
[TBL] [Abstract][Full Text] [Related]
3. An allosteric site enables fine-tuning of cathepsin K by diverse effectors.
Novinec M; Rebernik M; Lenarčič B
FEBS Lett; 2016 Dec; 590(24):4507-4518. PubMed ID: 27859061
[TBL] [Abstract][Full Text] [Related]
4. Computational investigation of conformational variability and allostery in cathepsin K and other related peptidases.
Novinec M
PLoS One; 2017; 12(8):e0182387. PubMed ID: 28771551
[TBL] [Abstract][Full Text] [Related]
5. Conformational flexibility and allosteric regulation of cathepsin K.
Novinec M; Kovacic L; Lenarcic B; Baici A
Biochem J; 2010 Jul; 429(2):379-89. PubMed ID: 20450492
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin K: a unique collagenolytic cysteine peptidase.
Novinec M; Lenarčič B
Biol Chem; 2013 Sep; 394(9):1163-79. PubMed ID: 23629523
[TBL] [Abstract][Full Text] [Related]
7. Rat cathepsin K: Enzymatic specificity and regulation of its collagenolytic activity.
Lecaille F; Chazeirat T; Bojarski KK; Renault J; Saidi A; Prasad VGNV; Samsonov S; Lalmanach G
Biochim Biophys Acta Proteins Proteom; 2020 Feb; 1868(2):140318. PubMed ID: 31740411
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential allosteric binding sites in cathepsin K based on intramolecular communication.
Rocha GV; Bastos LS; Costa MGS
Proteins; 2020 Dec; 88(12):1675-1687. PubMed ID: 32683717
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of Inhibitory Activity by Combining Allosteric Inhibitors Putatively Binding to Different Allosteric Sites on Cathepsin K.
Sato S; Yamamoto K; Ito M; Nishino K; Otsuka T; Irie K; Nagao M
Molecules; 2023 May; 28(10):. PubMed ID: 37241936
[TBL] [Abstract][Full Text] [Related]
10. Clusterin is a specific stabilizer and liberator of extracellular cathepsin K.
Novinec M; Lenarčič B; Baici A
FEBS Lett; 2012 Apr; 586(7):1062-6. PubMed ID: 22569264
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of collagen fiber degradation by cathepsin K.
Aguda AH; Panwar P; Du X; Nguyen NT; Brayer GD; Brömme D
Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17474-9. PubMed ID: 25422423
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and kinetic characterization of hyperbolic inhibitors of human cathepsins K and S based on a succinimide scaffold.
Goričan T; Ciber L; Petek N; Svete J; Novinec M
Bioorg Chem; 2021 Oct; 115():105213. PubMed ID: 34364050
[TBL] [Abstract][Full Text] [Related]
13. Human cathepsin L, a papain-like collagenase without proline specificity.
Korenč M; Lenarčič B; Novinec M
FEBS J; 2015 Nov; 282(22):4328-40. PubMed ID: 26306868
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Costa AG; Cusano NE; Silva BC; Cremers S; Bilezikian JP
Nat Rev Rheumatol; 2011 Jun; 7(8):447-56. PubMed ID: 21670768
[TBL] [Abstract][Full Text] [Related]
15. A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K.
Law S; Panwar P; Li J; Aguda AH; Jamroz A; Guido RVC; Brömme D
PLoS One; 2017; 12(10):e0186869. PubMed ID: 29088253
[TBL] [Abstract][Full Text] [Related]
16. Tailoring small molecules for an allosteric site on procaspase-6.
Murray J; Giannetti AM; Steffek M; Gibbons P; Hearn BR; Cohen F; Tam C; Pozniak C; Bravo B; Lewcock J; Jaishankar P; Ly CQ; Zhao X; Tang Y; Chugha P; Arkin MR; Flygare J; Renslo AR
ChemMedChem; 2014 Jan; 9(1):73-7, 2. PubMed ID: 24259468
[TBL] [Abstract][Full Text] [Related]
17. Recent computational advances in the identification of allosteric sites in proteins.
Lu S; Huang W; Zhang J
Drug Discov Today; 2014 Oct; 19(10):1595-600. PubMed ID: 25107670
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
Thompson SK; Smith WW; Zhao B; Halbert SM; Tomaszek TA; Tew DG; Levy MA; Janson CA; DAlessio KJ; McQueney MS; Kurdyla J; Jones CS; DesJarlais RL; Abdel-Meguid SS; Veber DF
J Med Chem; 1998 Oct; 41(21):3923-7. PubMed ID: 9767629
[TBL] [Abstract][Full Text] [Related]
19. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
Black WC; Percival MD
Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine.
Sivaraman J; Nägler DK; Zhang R; Ménard R; Cygler M
J Mol Biol; 2000 Jan; 295(4):939-51. PubMed ID: 10656802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
